CANDRIAM BIOTECHNOLOGY | Big move in Biogen stock

Today, Tuesday 22nd, Biogen stock is up 35% at the time of writing as the company surprisingly announced the intention to file Alzheimer’s drug Aducanumab with the FDA.

As a reminder, the drug failed during an interim futility analysis earlier this year, and the program was stopped. The company however did a further analysis of those phase III trials at a later time which included more patients that reached the high dose of the drug and that were longer on treatment on this high dose, and the results are much more supportive of approval.

Biogen ran the data with external consultants and (according public info from the company) also with the FDA, and then decided to eventually file. We looked at the data and though it is a long discussion, we can see the logic…

Lesen Sie hier weiter
Zurück Fonds im Visier | MARTAGON Solid Plus
Nächste Pictet-Robotics – Die nächste Stufe